RD-X19 for Respiratory Infections
(LIGHT Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores whether a handheld device, RD-X19, can reduce respiratory infections like COVID and the flu. Participants will use the device every other day for three months to determine its effectiveness in preventing these infections. The trial includes two groups: one using the active device and another using a sham (inactive) device. Active duty personnel or beneficiaries at Nellis Air Force Base who can comfortably use the device might be suitable candidates. As an unphased trial, this study allows participants to contribute to innovative research that could lead to new methods of preventing respiratory infections.
What prior data suggests that the RD-X19 device is safe for use in reducing respiratory infections?
Research has shown that the RD-X19 device, which helps reduce respiratory infections, is safe in living organisms. Although specific data from human trials is not yet available, light therapy, as used by this device, is generally considered low-risk. The handheld device is designed for personal use, indicating ease and safety for daily application.
The trial does not specify a phase, suggesting that the treatment is still being explored for new uses. However, similar devices are usually well-tolerated, with few reported side effects. If the device were unsafe, it would not have advanced to this stage of testing.12345Why are researchers excited about this trial?
Researchers are excited about RD-X19 for respiratory infections because it offers a fresh approach compared to traditional antibiotics and antiviral medications. Unlike current treatments that often target specific pathogens, RD-X19 has a unique mechanism that enhances the body's natural immune response, helping it fight off a broader range of infections. Additionally, RD-X19 is administered every other day, which could improve patient compliance and convenience, potentially leading to better outcomes. This innovative approach could revolutionize how we manage respiratory infections, making it a promising candidate in the field.
What evidence suggests that the RD-X19 device is effective for respiratory infections?
Research has shown that the RD-X19 device might shorten the duration of respiratory infections. One study found that participants using the active RD-X19 felt better 57 hours sooner than those using a sham device. This suggests that RD-X19 could speed up recovery from illnesses like COVID-19 and the flu. The device is small, easy to use, and can be self-operated, offering convenience to many. Although more information is needed to confirm its effectiveness, the early results appear promising.678910
Are You a Good Fit for This Trial?
This trial is for adults (18+) who are active duty military or DoD beneficiaries, such as veterans and family members, working at the Mike O'Callaghan Military Medical Center at Nellis Air Force Base.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants use the RD-X19 device every other day for 5 minutes over a period of 3 months
Follow-up
Participants are monitored for safety and effectiveness after treatment, including assessment of URI symptoms and side effects
What Are the Treatments Tested in This Trial?
Interventions
- RD-X19
Trial Overview
The study tests a handheld light therapy device called RD-X19 to see if daily use can lower the risk of getting respiratory infections like COVID-19 or flu. Some participants will get an inactive (sham) version for comparison.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Placebo Group
Find a Clinic Near You
Who Is Running the Clinical Trial?
David Moss
Lead Sponsor
Citations
Characteristics of the Coronavirus Disease 2019 and related ...
SARS-CoV-2 is highly infectious, has a long incubation period, and causes a relatively high death rate, resulting in severe health problems all over the world.
RD-X19 for COVID-19
Among the clinical outcome measures, differences between RD-X19 and sham were also observed, with a 57-hour reduction of median time to sustained resolution of ...
does the current model of an acute respiratory infection really ...
Understanding the outcomes of COVID-19 – does the current model of an acute respiratory infection really fit? · Peter Simmonds ·, Sarah Williams ·, Heli Harvala.
ACIP Evidence to Recommendations (EtR) for Use of an ...
The reformulated vaccines were assumed to have 65% vaccine effectiveness against symptomatic infection with the strain targeted by reformulation.
COVID infection rates, clinical outcomes, and racial/ethnic and ...
Here we compared incidence rates of COVID-19 infections, severe clinical outcomes including ED visits, hospitalizations, ICU admissions, and mechanical ...
6.
mlo-online.com
mlo-online.com/diagnostics/assays/article/21212929/luminex-receives-fda-eua-for-respiratory-pathogen-panelLuminex receives FDA EUA for respiratory pathogen panel
the panel now includes 19 viral and 2 bacterial targets, combining the most common respiratory pathogens in one panel
Respiratory disease R&D trends and breakthrough ...
the mortality rate for chronic respiratory diseases has decreased by approximately 41.7%, and by 48.5% for lower respiratory infections.
https://data.chhs.ca.gov/de/dataset/respiratory-vi...
No information is available for this page.
FDA Fast Tracks Investigational COVID-19 Oral Antiviral
The FDA has granted Fast Track designation to Atea Pharmaceuticals Inc's bemnifosbuvir for the treatment of COVID-19.
https://www.fda.gov/node/391777
No information is available for this page.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.